| Dr Bryan James Beals, MD | |
|
9100 Andermatt Dr Ste 1, Lincoln, NE 68526-6700 | |
| (402) 434-2730 | |
| (402) 434-3970 |
| Full Name | Dr Bryan James Beals |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 9100 Andermatt Dr Ste 1, Lincoln, Nebraska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710141288 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 5833 (Nebraska) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 25941 (Nebraska) | Primary |
| Entity Name | Pine Lake Behavioral Health, Llc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003310061 PECOS PAC ID: 7810250164 Enrollment ID: O20180418003008 |
News Archive
A new University of Iowa study suggests that metabolism of plant-based dietary substances by specific gut bacteria, which are lacking in patients with multiple sclerosis (MS), may provide protection against the disease.
Takeda Pharmaceutical Company Limited and Zinfandel Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide licensing agreement regarding Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease in high-risk older adults with normal cognition. The companies will study pioglitazone in connection with the TOMM40 biomarker and Alzheimer's disease.
Pfizer announced today that the European Commission has approved Vyndaqel (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy.
The Conservatives have claimed that a halt in the Labour planned rise in National Insurance (NI) could mean £200 million in savings for the NHS and provide doctors more power to choose which drugs especially those treating cancer are made available.
Data from a Phase II study of eltrombopag, an oral investigational drug that increases the production of platelets, demonstrate that the compound was effective in increasing platelet counts in patients with chronic Immune Thrombocytopenic Purpura (ITP), a disorder characterized by episodes of frequent spontaneous bruising, mucosal bleeding, and in severe cases intracranial hemorrhage, and acute episodes of severe bleeding.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bryan James Beals, MD 9100 Andermatt Dr Ste 1, Lincoln, NE 68526-6700 Ph: (402) 434-2730 | Dr Bryan James Beals, MD 9100 Andermatt Dr Ste 1, Lincoln, NE 68526-6700 Ph: (402) 434-2730 |
News Archive
A new University of Iowa study suggests that metabolism of plant-based dietary substances by specific gut bacteria, which are lacking in patients with multiple sclerosis (MS), may provide protection against the disease.
Takeda Pharmaceutical Company Limited and Zinfandel Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide licensing agreement regarding Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease in high-risk older adults with normal cognition. The companies will study pioglitazone in connection with the TOMM40 biomarker and Alzheimer's disease.
Pfizer announced today that the European Commission has approved Vyndaqel (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy.
The Conservatives have claimed that a halt in the Labour planned rise in National Insurance (NI) could mean £200 million in savings for the NHS and provide doctors more power to choose which drugs especially those treating cancer are made available.
Data from a Phase II study of eltrombopag, an oral investigational drug that increases the production of platelets, demonstrate that the compound was effective in increasing platelet counts in patients with chronic Immune Thrombocytopenic Purpura (ITP), a disorder characterized by episodes of frequent spontaneous bruising, mucosal bleeding, and in severe cases intracranial hemorrhage, and acute episodes of severe bleeding.
› Verified 3 days ago
Stephanie Sutton, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 550 N 19th St, Lincoln, NE 68588 Phone: 402-472-5000 | |
Dr. Walter J Duffy, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 8101 O St, Suite 300, Lincoln, NE 68510 Phone: 402-476-6060 Fax: 402-476-6809 | |
Soa Yuc Lee, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 600 S 70th St, Lincoln, NE 68510 Phone: 402-489-3802 | |
Dianna M Clyne, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4444 South 86th St, Suite 102, Lincoln, NE 68526 Phone: 402-476-7557 Fax: 402-769-9912 | |
Michael William Vavra, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2222 S 16th St Ste 340, Lincoln, NE 68502 Phone: 402-483-8534 Fax: 402-483-8531 | |
Zakaria Siddiqui, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2221 S 17th St, Suite 202, Lincoln, NE 68502 Phone: 402-483-8555 Fax: 402-483-8554 | |
Ana Luisa Delgado, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 7441 O St Ste 104, Lincoln, NE 68510 Phone: 402-853-0993 Fax: 402-853-0197 |